The ELF which stands for Enhanced Liver Fibrosis is a routine blood test used as an aid in the diagnosis and assessment of liver fibrosis severity.
This test offers the following benefits like minimal patient discomfort and identification of significant liver disease. Because ELF uses a blood sample rather than an invasive biopsy, it can be used to monitor the same patient over time.
The National Institute for Health and Care Excellence (NICE) issued evidence based guidelines recommending the use of the Enhanced Liver Fibrosis (ELF) blood test to test and monitor advanced liver fibrosis in, people diagnosed with Non Alcoholic Fatty Liver Disease (NAFLD).
The ELF Blood Test combines three serum biomarkers, which have been shown to correlate to the level of liver fibrosis assessed by liver biopsy. These biomarkers include are hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1).
The algorithm measures each of these markers by immunoassay, to create an ELF Score. This score classifies mild, moderate, and severe fibrosis. The ELF Blood Test can be performed in a physician's office or health center.